Takasuna K, Kasai Y, Usui C, Takahashi M, Hirohashi M, Tamura K, Takayama S
Drug Safety Research Center, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
Arzneimittelforschung. 1992 Mar;43(3A):408-18.
The general pharmacological properties of (-)-(S)-9-fluoro-2,3-dihydro-3- methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4] benzoxazine-6-carboxylic acid hemihydrate (levofloxacin, DR-3355, CAS 100986-85-4), an optically active isomer of ofloxacin, were examined. 1. Central nervous system (CNS): DR-3355 at 200-600 mg/kg p.o. showed depressant activity on the CNS, as was indicated by the depressant syndrome (mice), decreased spontaneous motor activity (mice) and hypothermia (mice and rabbits). In the cat behavior and EEG experiments, it had both stimulant and depressant effects at 30-100 mg/kg i.p., and caused transient slow waves followed by seizures at 20-30 mg/kg i.v. DR-3355 had no effect on convulsion, hexobarbital anesthesia, pain reaction to a tail pinch, or conditioned avoidance response, except that it showed mild analgesic activity in acetic acid writhing at 600 mg/kg p.o. 2. Respiratory and cardiovascular system: DR-3355 produced a hypotensive and a bradycardiac effect after the rapid i.v. injection of 6 mg/kg or more in anesthetized dogs, accompanied by an increase in plasma histamine concentration. Both changes were markedly reduced when the test drug was administered by continuous i.v. infusion. 3. Autonomic nervous system: DR-3355 inhibited nictitating membrane contraction induced by both pre- and post-ganglionic stimulation, and inhibited the depressor response to acetylcholine at 20 mg/kg i.v. It had no influence on pupil size or on pressor response to norepinephrine. 4. Gastrointestinal system: DR-3355 at 600 mg/kg p.o. inhibited gastric secretion. Dog gastrointestinal motility was slightly inhibited, and was then stimulated over the dose range of 2-20 mg/kg i.v. It had no influence on gastrointestinal propulsion, the gastric emptying rate or the gastric mucosa. 5. Isolated smooth muscle: At a concentration of 5 x 10(-4) g/ml, DR-3355 was devoid of spasmogenic or smasmolytic activity, except for showing a slight relaxation effect (trachea), inhibition of nicotine-induced contraction (ileum) and spontaneous or oxytocin-induced motility (pregnant uterus). 6. Miscellaneous: DR-3355 inhibited the urine output and carrageenin-induced paw edema at 600 mg/kg p.o. It had no effect on skeletal muscle contraction or the corneal reflex.
对氧氟沙星的光学活性异构体(-)-(S)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并[1,2,3 - de][1,4]苯并恶嗪-6-羧酸半水合物(左氧氟沙星,DR - 3355,CAS 100986 - 85 - 4)的一般药理学特性进行了研究。1. 中枢神经系统(CNS):口服200 - 600mg/kg的DR - 3355对中枢神经系统有抑制活性,表现为抑制综合征(小鼠)、自发运动活动减少(小鼠)和体温过低(小鼠和兔子)。在猫的行为和脑电图实验中,腹腔注射30 - 100mg/kg时具有兴奋和抑制作用,静脉注射20 - 30mg/kg时会引起短暂的慢波随后发作。DR - 3355对惊厥、己巴比妥麻醉、夹尾疼痛反应或条件回避反应无影响,只是口服600mg/kg时在醋酸扭体实验中显示出轻度镇痛活性。2. 呼吸和心血管系统:在麻醉犬中快速静脉注射6mg/kg或更多剂量的DR - 3355后会产生降压和心动过缓作用,同时血浆组胺浓度升高。当通过静脉连续输注给药时,这两种变化均明显减轻。3. 自主神经系统:DR - 3355抑制节前和节后刺激诱导的瞬膜收缩,并在静脉注射20mg/kg时抑制对乙酰胆碱的降压反应。它对瞳孔大小或去甲肾上腺素的升压反应没有影响。4. 胃肠道系统:口服600mg/kg的DR - 3355抑制胃液分泌。犬的胃肠蠕动略有抑制,然后在静脉注射2 - 20mg/kg的剂量范围内受到刺激。它对胃肠推进、胃排空率或胃黏膜没有影响。5. 离体平滑肌:在浓度为5×10(-4)g/ml时,DR - 3355除了对气管有轻微舒张作用、抑制尼古丁诱导的回肠收缩以及自发或催产素诱导的妊娠子宫运动外,没有致痉或解痉活性。6. 其他:口服600mg/kg的DR - 3355抑制尿量和角叉菜胶诱导的爪肿胀。它对骨骼肌收缩或角膜反射没有影响。